Solutions for MedTech Startups

The MedTech Startup Landscape

Launching a medical device as a startup is a bold and complex endeavor. From navigating regulatory hurdles to securing funding and proving clinical value, MedTech innovators face a steep climb.
The reality is stark: over 75% of MedTech startups fail, often due to regulatory delays, lack of market demand, or insufficient funding. These challenges are compounded by the high cost of clinical trials and the need for specialized regulatory expertise.

That’s where NAMSA Startup Solutions steps in. We offer early-stage MedTech companies a tailored, integrated, end-to-end support system, from context of use development to preclinical strategy and regulatory planning to clinical execution and market access. Our dedicated Startup Solutions team helps you avoid costly missteps, accelerate timelines, and build investor confidence with data-driven strategies and global expertise.

NAMSA Startup Solutions

Every year NAMSA works with 1,000+ MedTech startups to help them bring new innovations to market successfully. With decades of experience in the MedTech space and a deep understanding of the unique challenges that early-stage companies face, NAMSA provides tailored, scalable solutions that accelerate development, reduce risk, and streamline the path to regulatory and commercial success. NAMSA is here to help startups succeed because it’s our mission to accelerate the introduction of new medical device technology than improve the lives of patients worldwide. We are your partner throughout the lifecycle of your medical device and your new company.

NAMSA Strategic Services: Aligning Vision with Execution

Bringing a medical device to market requires more than innovation, it demands a clear, actionable strategy. NAMSA’s Strategic Services are designed to help MedTech startups build that foundation with precision and execute with confidence. Whether you’re preparing for regulatory engagement, investor meetings, or internal planning, our team delivers high-impact tools to guide your next steps.  Below are the services we recommend to kick start your journey:

• Strategic Summary 
  High-level, cross-functional roadmap covering regulatory, clinical, preclinical and medical device testing areas outlining key milestones and parallel development opportunities to reduce time, cost, and risk.
• Product Development Plan (PDP) 
  Detailed, stage appropriate roadmap translated into a Gantt-style schedule with defined activities, timelines, and dependencies to guide execution.
• Regulatory Strategy  
  Deep dive regulatory strategy for an indicated market and device including a comparative pathway analysis and estimated market submission guidelines.
• Clinical Strategy 
  Clinical evidence generation strategy that includes the design of first-in-human and pivotal studies, with defined, detailed endpoints, target population, and feasibility considerations.
• Reimbursement Strategy 
  Reimbursement strategy reviewing and summarizing existing coding, coverage and payment opportunities in the U.S., and how to establish new codes that will ensure payment for your innovation.
• Investor Pitch Deck Materials 
  A high level summary of regulatory, clinical and/or reimbursement strategies to be incorporated in the Investor Pitch Deck that attracts and keeps investors’ attention and establishes credibility.

By taking advantage of this solution, you can reassure investors that you are on the right path and reduce the risk associated with your proposed approach.

NAMSA Preclinical for Product Development Insights

Early‑stage medical device innovators often face a critical challenge: gaining timely, reliable insight into how their technologies perform in a realistic preclinical environment. Start‑Ups need a way to test, learn, and refine quickly—without navigating complex processes or large‑scale study commitments.

NAMSA’s Preclinical Insights program was created specifically to support this need. Built for small and emerging companies, Preclinical Insights provides a client with a streamlined pathway to market, with early technical feedback and expert perspective to help shape the development strategy. Rather than offering a full study program, this service focuses on giving Start‑Ups the opportunity to explore feasibility, strengthen decision‑making, and identify the right next steps with confidence.

Through guided engagement with NAMSA’s preclinical experts, Start‑Ups gain clarity on device performance and future considerations—helping them move forward with greater certainty and reduced risk.

Whether your team is working to validate a concept, refine a prototype, or better understand your device’s behavior early in development, Preclinical Insights provides a direct, supportive way to begin that journey.

NAMSA Fractional Executive Advisory Services for Strategic Leadership

Early-stage MedTech companies often face critical gaps in leadership and specialized expertise that can slow progress and increase risk. NAMSA’s Fractional Executive Advisory Services are designed to fill those gaps with seasoned professionals who bring strategic insight and operational excellence to your team – without the cost and time overhead of full-time hires. While NAMSA offers a variety of fractional roles, here are the ones most often selected by our Startup partners:

• Fractional Executive-level Strategy Advisor 
  Plays a pivotal role in shaping both clinical and business strategy—offering executive-level input on clinical investigations, product development, market positioning, reimbursement, and investor engagement.
• Fractional Regulatory Affairs Advisor 
  Provides strategic regulatory leadership—developing, refining, and guiding regulatory pathways while navigating global requirements with confidence to support successful submissions and long‑term compliance.
• Fractional Clinical Research Advisor 
  Provides senior‑level guidance on clinical development—shaping study designs, evidence‑generation plans, and trial execution strategies to ensure your clinical program supports regulatory approval, reimbursement, and investor expectations.
• Fractional Quality Advisor 
  Offers expert leadership in building and refining your Quality Management System (QMS), ensuring compliance with global standards while supporting scalable processes across design controls, risk management, supplier oversight, and manufacturing readiness.

Learn more about clinical outsourcing services

These experts integrate seamlessly into your organization, providing the high-level guidance and executional support needed to keep your program moving forward – on time and on target.  Reach out today if you want to inquire about our full fractional staff service offering.

Struggling to Build Your First Biological Evaluation Plan? We Can Help.

Many startups developing their first medical device aren’t sure where to begin with a Biological Evaluation Plan (BEP) —or how to ensure it will meet regulatory expectations. NAMSA’s CoPilot Program was created specifically for early-stage companies that need structured guidance without the high upfront cost.

With this program, you receive:

• A step-by-step BEP template with clear instructions 
  Includes guidance, tips, and practical examples to help you understand what regulators expect and how to structure your plan correctly.
• On-demand review and expert consultation 
  A NAMSA biological safety expert will support you at any point during your BEP development, ensuring you stay on track and avoid common pitfalls.
• Confidence in regulatory readiness 
  You’ll leave with a BEP that not only meets but exceeds global regulatory expectations—fully suitable for submission in any major market.
• Click here to learn more